Please ensure Javascript is enabled for purposes of website accessibility

Merck to Begin Pivotal COVID-19 Antiviral Studies in September

By Cory Renauer – Updated Aug 6, 2020 at 10:55AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the company's efforts to address the COVID-19 pandemic is moving forward faster than expected.

During Merck's (MRK 1.09%) second-quarter earnings call on Friday, the company's head of research and development discussed progress on a potential new treatment for COVID-19 patients. The antiviral candidate MK-4482 is a nucleoside analog that makes it hard for SARS-CoV-2 to replicate itself in the laboratory and is being developed in partnership with Ridgeback Biotherapeutics.

Following encouraging results from an ascending dose study, Merck thinks MK-4482 is well-tolerated at levels that should be more than enough to stop SARS-CoV-2 in its tracks. Based on preliminary results from three mid-stage studies, Roger Perlmutter, president of Merck Research Laboratories, believes the company will begin a pair of large pivotal trials in September. 

Coronavirus sample vials and a syringe.

Image source: Getty Images.

Merck is also in discussion with the National Institute of Allergy and Infectious Diseases (NIAID) about a large outpatient study to be conducted under the institute's supervision.

In a laboratory setting, MK-4882 has shown an ability to combat viruses that have acquired mutations, rendering them resistant to the only antiviral treatment currently available for COVID-19 patients, remdesivir from Gilead Sciences (GILD 2.08%). And Merck's coronavirus antiviral candidate could have another leg up on Gilead's treatment. Remdesivir is delivered as an intravenous infusion, while MK-4482 is an easy-to-swallow tablet.

Merck is moving pretty quickly with MK-4882, but it's still far behind an injectable antiviral treatment candidate for COVID-19 from Regeneron (REGN 1.50%). The dual-antibody cocktail called REGN-COV2 has already entered pivotal studies with COVID-19 patients in partnership with NIAID.

Editor's Note: This article was updated to reflect that the drug MK-4882 is being developed in collaboration with Ridgeback Biotherapeutics.

Cory Renauer owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.78 (1.09%) $0.94
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$63.93 (2.08%) $1.30
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$705.42 (1.50%) $10.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.